Andrew Musgrave
Welcome back to ASX Briefs, and today we're looking at the intersection of life sciences and digital health. And joining me today is Damian Wood, the CEO of EVE Health Group. Damien, thanks for joining me today and welcome to the ASX Briefs podcast.
Damian Wood
Thanks, Andrew. Thanks for having me.
Andrew Musgrave
Now Damien, for those unfamiliar with EVE Health Group, can you give us a brief overview of the company?
Damian Wood
Yeah, sure. EVE Health Group, we're an emerging pharmaceutical company. In particular, we focus on women's health and men's health. In fact, in 2025, we launched our first women's health product, which is called Dyspro. It's a herbal-based chewable gummy. It contains a blend of cannabinoids for the treatment of period pain. So, it's called Dyspro because dysmenorrhea is the medical term for period pain. The reason why we've developed this formulation is because it targets a market that is really not really well treated. So, we've noticed in recent years there's been more and more talk about women's health, and in particular period pain. We know it costs the Australian economy 16 billion Australian dollars in terms of lost production. So, we've got a formulation science team that scour all the literature and look at various products and how to make them and what active ingredients to put in. And so, it's identifying a problem, and this is a great solution. And yeah, product selling, the uptake is good. And yeah, we can talk more about the that product. And we also work in the men's health space, and we've just recently launched a product called Libbo. It's an oral soluble film for the treatment of erectile dysfunction. It dissolves in the mouth within 15 seconds, and it has an onset of action within about 15 minutes. So, it's a very rapid acting formulation. So, in summary, men's health, women's health, pharmaceutical company, first two products launched into the Australian market. And yeah, so that's a snapshot of what we've achieved so far in less than a year, which is great.
Andrew Musgrave
Okay, excellent. Now the erectile dysfunction is a well-established market. So, what is the opportunity for EVE in this space?
Damian Wood
Yeah, so the erectile dysfunction market, we're targeting Australia initially. It's obvious because that's where we're based and we're looking at a hundred-million-dollar market size in Australia. So, with our product Libbo, it's uniquely different. It's the first pharmaceutical manufactured oral soluble film offering in Australia contains the active ingredient Vardenafil. We feel that this is the biggest opportunity in the next generation product compared to the little blue pill that was launched 27 years ago. So initially targeting the Australian market through telehealth clinics, and then we're also working closely with the TGA, and we're doing ongoing clinical studies to get this product listed with the TGA, our regulators, for export markets. So, towards the end of 2026, we'll certainly be embedded into overseas markets with our product Libbo, which is super exciting.
Andrew Musgrave
Okay, and what about the Stiff Issue platform? How is that expected to arouse the market?
Damian Wood
Yes, so the stiff issue, you know, it's about time that that we as men and us as a pharmaceutical company address the elephant in the room. And StiffIssue.com is a platform that offers education on erectile dysfunction. We know that about 40% of men at any time during their life do suffer from at least one episode of erectile dysfunction or unsatisfactory performance in the bedroom. We know that that prevalence becomes more as we get older as men. So, the stiffissue.com, and we've named it that because it literally is a stiff issue in more than one sense of the term. It's primarily an education platform for patients, but it also gives hyperlinks to our partner clinics, so Teledocs Clinic and also HubMed. These are two separate clinics that offer telehealth services whereby a patient can make a booking. They have a telephone conversation with a nurse practitioner or a medical practitioner. And those practitioners and patients during the consult determine whether Libbo is the right product for that patient. They'll be issued a script, which the patient can either take to a pharmacy or even more discreetly, the electronic prescription can be emailed to the pharmacy and the patient can opt for home delivery. So, with a sensitive issue like erectile dysfunction, we have the technology and the regulatory framework that allows a discrete telephone call with a specialist prescriber and also home delivery for the patient. So, we feel that this supply chain framework that we're now embedded in will really help with the support of Stiffissue.com to get the awareness out there and for the practitioner and the patient to make the best-informed decision about choosing Libbo as a as a product offering.
Andrew Musgrave
Now, looking at other markets, how does EVE plan to scale Libbo offshore? And what share of the international erectile dysfunction market do you believe is realistically achievable over the next three to five years?
Damian Wood
Yeah. So, yes, we do have plans to enter into the export markets. We know that will take about six months. So, we're looking at the middle of 2026 to get TGA approval to export our Libbo men's health offering and also our Dyspro women's health offering for period pain into those export markets. One of the major advantages of both our formulations for women's health and men's health is that they don't contain alcohol. And one of our primary target markets for overseas is the Middle East North African markets for our men's health product Libbo, the oral soluble film. Because it doesn't contain alcohol in those Islamic regions and those Islamic countries, having an alcohol-free product is far more acceptable than having one that contains alcohol. The reason why we've we're targeting the Middle East in particular, so Saudi Arabia, Dubai, is because in those regions for the erectile dysfunction products, they actually fetch a retail price of about three to five times that in Australia, Europe, or even the US. So, that's going to be our first overseas target market. In fact, we're actually talking to potential product sponsors for imports and distributors in the Middle East. And we've also started discussions with European and UK off-takers. So, we're looking at a global market in erectile dysfunction of 5 billion US dollars. And in terms of answering your question, what percentage of that market are we expecting to take in the next three to five years? Well, the short answer is as much as possible. But with this product formulation that is uniquely different to a tablet, it's discrete, you it dissolves in the tongue without requiring any water, it's minty fresh, which has an advantage, and it can be used spontaneously in that it works within 15 minutes, as opposed to taking 60 to 90 minutes if a tablet was taken. The reason it works so quickly is that because it actually bypasses the liver. It absorbs from under the tongue and inside the cheek and goes direct to the site of action, being the penis. And, so yeah, it's difficult to actually pinpoint what percentage of the market we're going to achieve. However, it is a uniquely different product that's easier to take, it works faster, and we can actually sell it about 30% cheaper than what tablets are currently being offered. So not only are we offering the patient something that works better, faster, we're also offering a cheaper option. So that's where we see our advantage to really rock the market in Australia and also those overseas markets.
Andrew Musgrave
Okay, now also are there any other products or technology that are in the pipeline that you can touch on?
Damian Wood
Yeah, that's a good point. We've actually got a formulation science team that we work with and in particular, we take water insoluble drugs, and we make them soluble. That's our IP that we have. We have patents protecting those IPs. So, we have a library of products, and in particular, what we're looking at, we're looking at the patent cliff, essentially what Big Pharma has controlled under patent for the last 20 years. And over the next two years, starting 2026, there's some significant number of products that are coming off patent that are worth over 100 billion US dollars in terms of their market size. Most of these products are presented currently by Big Pharma in a tablet or a capsule form. They're water-insoluble drugs, only a small percentage of the drug, about 10 to 15%, is actually absorbed and has a therapeutic effect. The other 85 to 90% of the drug is just excreted through the gut, not used. With our technology of knowing how to solubilize these water-insoluble drugs, it gives us an opportunity to present these active ingredients or medicines in a different dosage form, whether it be something topical, as in a rub on the skin, or whether it be a nasal spray for dementia, whether it's an oral spray, even for treatments like erectile dysfunction or other such treatments. So, one example is a drug called apixaban. So, apixaban is a medicine that is used to treat and also prevent unwanted blood clots, deep vein thromboses in the legs, or pulmonary emboli, which is clots in the lungs. So, these are life-threatening blood clots if a patient is unfortunate to get them. So, patients are going for certain types of surgeries, knee replacements, hip replacements.
Quite often they routinely have anywhere from four weeks to six weeks' worth of therapy after as a tablet. Because the absorption is not that great. Some patients do still get unwanted blood clots. With our formulation, we can present them in different ways. We can present the drug in an oral soluble film for those patients who have swallowing difficulties, not just for apixaban, but for all sorts of different water-insoluble drugs. So we've got real opportunity to radically improve the healthcare sector for those patients with unsafe swallows, those older patients that are on polypharmacy, which means lots of different medicines, who would prefer to have something as a spray, as an oral soluble film, to just help them take their medicines easier and more effective rather than the risk of not taking the medicines because they just fed up of swallowing lots and lots of tablets. And that does happen. There is a huge economic burden by patients not taking their medicines and they bounce back into hospital time and time again. So, so yeah, so that's what we do. We take existing active ingredients that are well known to the regulators. We're not we're not creating new active ingredients, we're taking existing active ingredients, but we're formulating them in a way that's more acceptable to patients, clinicians, and improves the healthcare outcomes for patients.
Andrew Musgrave
Okay, now just to wrap things up, if we're sitting here in 12 months' time, what does success look like for EVE Health Group?
Damian Wood
Yeah, so what success looks like is that we've further rolled out two existing products, Dyspro and Libbo. We've opened up export markets, and also close to bringing newer products onto the market in those different dosage forms that are more acceptable to patients. And with that brings increase in revenue in Australia and also revenue through those overseas markets, including opportunities for licensing royalties and leaning on those companies overseas that we're already engaged with, that have their own frameworks in place for marketing and sales, so that we don't have to invest teams overseas to be able to go out and launch and increase the sales revenues for those products. So, licensing opportunities and royalty opportunities is ways that we can exponentially increase our global revenue opportunities.
Andrew Musgrave
Okay, Damien. Well, it's been great to chat today, so thanks for your time, and we look forward to further updates from EVE Health Group in the upcoming months.
Damian Wood
Great, thank you so much, Andrew.
Andrew Musgrave
That concludes this episode of ASX Briefs. Don't forget to subscribe, and we look forward to catching you on our next episode.